Assessment of human immune responses to H7 avian influenza virus of pandemic potential: results from a placebo-controlled, randomized double-blind phase I study of live attenuated H7N3 influenza vaccine

Larisa Rudenko, Irina Kiseleva, Anatoly N Naykhin, Marianna Erofeeva, Marina Stukova, Svetlana Donina, Galina Petukhova, Maria Pisareva, Vera Krivitskaya, Michael Grudinin, Zhanna Buzitskaya, Irina Isakova-Sivak, Svetlana Kuznetsova, Natalie Larionova, Julia Desheva, Irina Dubrovina, Alexandra Nikiforova, John C Victor, Kathy Neuzil, Jorge Flores, Vadim Tsvetnitsky, Oleg Kiselev, Larisa Rudenko, Irina Kiseleva, Anatoly N Naykhin, Marianna Erofeeva, Marina Stukova, Svetlana Donina, Galina Petukhova, Maria Pisareva, Vera Krivitskaya, Michael Grudinin, Zhanna Buzitskaya, Irina Isakova-Sivak, Svetlana Kuznetsova, Natalie Larionova, Julia Desheva, Irina Dubrovina, Alexandra Nikiforova, John C Victor, Kathy Neuzil, Jorge Flores, Vadim Tsvetnitsky, Oleg Kiselev

Abstract

Introduction: Live attenuated influenza vaccines (LAIVs) are being developed to protect humans against future epidemics and pandemics. This study describes the results of a double-blinded randomized placebo-controlled phase I clinical trial of cold-adapted and temperature sensitive H7N3 live attenuated influenza vaccine candidate in healthy seronegative adults.

Objective: The goal of the study was to evaluate the safety, tolerability, immunogenicity and potential shedding and transmission of H7N3 LAIV against H7 avian influenza virus of pandemic potential.

Methods and findings: Two doses of H7N3 LAIV or placebo were administered to 40 randomly divided subjects (30 received vaccine and 10 placebo). The presence of influenza A virus RNA in nasal swabs was detected in 60.0% and 51.7% of subjects after the first and second vaccination, respectively. In addition, vaccine virus was not detected among placebo recipients demonstrating the absence of person-to-person transmission. The H7N3 live attenuated influenza vaccine demonstrated a good safety profile and was well tolerated. The two-dose immunization resulted in measurable serum and local antibody production and in generation of antigen-specific CD4⁺ and CD8⁺ memory T cells. Composite analysis of the immune response which included hemagglutinin inhibition assay, microneutralization tests, and measures of IgG and IgA and virus-specific T cells showed that the majority (86.2%) of vaccine recipients developed serum and/or local antibodies responses and generated CD4⁺ and CD8⁺ memory T cells.

Conclusions: The H7N3 LAIV was safe and well tolerated, immunogenic in healthy seronegative adults and elicited production of antibodies broadly reactive against the newly emerged H7N9 avian influenza virus.

Trial registration: ClinicalTrials.gov NCT01511419.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Trial profile.
Figure 1. Trial profile.
CONSORT 2010 Flow Diagram. The schema graphically outlines the design and conduct of the clinical study. One subject dropped out from the study prior to receiving the second dose of vaccine because of an adverse event not related to the vaccination (adenovirus infection on Day 28 confirmed by PCR).

References

    1. Rudenko L, Desheva J, Korovkin S, Mironov A, Rekstin A, et al. (2008) Safety and immunogenicity of live attenuated influenza reassortant H5 vaccine (phase I–II clinical trials). Influenza Other Respi Viruses 2 (6) 203–209.
    1. Desheva JA, Rudenko LG, Rekstin AR, Swayne D, Cox NJ et al... (2007) Development of candidate H7N3 live attenuated cold–adapted influenza vaccine. In: Proceedings of the International Conference on Options for the Control of Influenza VI, Toronto, Ontario, Canada, June 17–23, 2007 (Ed. Jacqueline M Katz). International Medical Press. 591–592.
    1. Alexandrova GI (1977) Use of the genetic recombination method for obtaining vaccinal strains of the influenza virus [Article in Russian]. Vopr Virusol 4: 387–395.
    1. WHO Manual on animal influenza diagnosis and surveillance (2002) Available: . Accessed 2013 Aug 12.
    1. Kiseleva I, Larionova N, Kuznetsov V, Rudenko L (2010) Phenotypic characteristics of novel swine–origin influenza A/California/07/2009 (H1N1) virus. Influenza Other Respi Viruses 4 (1) 1–5.
    1. Reed LJ, Muench H (1938) A simple method of estimating fifty per cent endpoints. Amer J Hygiene 27 (3) 493–497.
    1. Hoffmann E, Stech J, Guan Y, Webster RG, Perez DR (2001) Universal primer set for the full–length amplification of all influenza A viruses. Arch Virol 146 (12) 2275–2289.
    1. Naikhin AN, Donina SA, Kustikova IuG, Katorgina LG, Rudenko LG (1997) Monoclonal immunoenzyme test–system for evaluating secretory immunity to influenza A and B viruses [Article in Russian]. Vopr Virusol 42: 212–216.
    1. Prussin C, Metcalfe DD (1995) Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti–cytokine antibodies. J Immunol Methods 188 (1) 117–128.
    1. He XS, Holmes TH, Zhang C, Mahmood K, Kemble GW, et al. (2006) Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol 80 (23) 11756–117566.
    1. Meijer A, Bosman A, van de Kamp EE, Wilbrink B, van Beest Holle Mdu R, et al. (2006) Measurement of antibodies to avian influenza virus A(H7N7) in humans by hemagglutination inhibition test. J Virol Methods 132 (1–2) 113–120.
    1. Talaat KR, Karron RA, Callahan KA, Luke CJ, DiLorenzo SC, et al. (2009) A live attenuated H7N3 influenza virus vaccine is well–tolerated and immunogenic in a phase I trial in healthy adults. Vaccine 27 (28) 3744–3753.
    1. Metreveli G, Zohari S, Ejdersund A, Berg M (2010) Phylogenetic analysis of the hemagglutinin gene of low pathogenic avian influenza virus H7N7 strains in mallards in northern Europe. Avian Dis 54 (1 Suppl) 453–456.
    1. Joseph T, McAuliffe J, Lu B, Jin H, Kemble G, et al. (2007) Evaluation of replication and pathogenicity of avian influenza A H7 subtype viruses in a mouse model. J Virol 81 (19) 10558–10566.
    1. Fouchier RA, Schneeberger PM, Rozendaal FW, Broekman JM, Kemink SA, et al. (2004) Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci USA 101 (5) 1356–1361.
    1. Mallory RM, Malkin E, Ambrose CS, Bellamy T, Shi L, et al. (2010) Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials. PLoS One 5 (10) e13755 doi:
    1. Requirements for influenza vaccine (inactivated) and for influenza vaccines (live) (1979) WHO Expert Committee on Biological Standardization. Thirtieth report, Annex 3. Geneva, World Health Organization (WHO Technical Report Series, No. 638). Available: . Accessed 2013 Aug 12.
    1. Points to consider on the development of live attenuated influenza vaccines (EMEA/CPMP/BWP/2289/01) (2003) Available: . Accessed 2013 Aug 12.
    1. WHO recommendations to assure the quality, safety, and efficacy of influenza vaccines (human, live attenuated) for intranasal administration (2009) Final Expert Committee on Biological Standardization. Available: . Accessed 2013 Aug 12.
    1. Petukhova G, Korenkov D, Chirkova T, Donina S, Rudenko L, et al. (2012) B– and T–cell memory elicited by a seasonal live attenuated reassortant influenza vaccine: assessment of local antibody avidity and virus–specific memory T–cells using trogocytosis–based method. Influenza Other Respi Viruses 6 (2) 119–126.
    1. Rudenko L, Bosch H, Kiseleva I, Mironov A, Naikhin A, et al. (2011) Live attenuated pandemic influenza vaccine: clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian−developed technology to WHO for pandemic influenza preparedness in developing countries. Vaccine 29 (1 Suppl) A40–A44.
    1. Chirkova TV, Naykhin AN, Petukhova GD, Korenkov DA, Donina SA, et al. (2011) Memory T–cell immune response in healthy young adults vaccinated with live attenuated influenza A (H5N2) vaccine. Clin Vaccine Immunol 18 (10) 1710–1718.
    1. Rudenko L, Isakova−Sivak I, Donina S (2013) H7N3 live attenuated influenza vaccine has a potential to protect against new H7N9 avian influenza virus. Vaccine 31 (42) 4702–4705.
    1. Metreveli G, Zohari S, Ejdersund A, Berg M (2010) Phylogenetic analysis of the hemagglutinin gene of low pathogenic avian influenza virus H7N7 strains in mallards in northern Europe. Avian Dis 54 (1 Suppl) 453–456.
    1. Kageyama T, Fujisaki S, Takashita E, Xu H, Yamada S, et al. (2013) Genetic analysis of novel avian A(H7N9) influenza viruses isolated from patients in China, February to April 2013. Euro Surveill 18 (15) pii = 20453 Available: . Accessed 2013 Aug 12.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren